Skip to main content
RDHL
NASDAQ Life Sciences

RedHill Biopharma Finalizes $6M Private Placement with Warrants, Securing Critical Capital at Significant Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.84
Mkt Cap
$4.225M
52W Low
$0.71
52W High
$3.31
52W Position info
18% above low
Off High info
75% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

RDHL sits 18% above its 52-week low of $0.71.

Summary

RedHill Biopharma has finalized a private placement to raise $6 million upfront, with potential for an additional $13.4 million from warrant exercises, providing critical capital but at a substantial dilutive cost to shareholders.


Key Events · Financing and Capital Events · RDHL

  • Private Placement Finalized

    Details of a private placement to raise $6 million upfront, with potential for an additional $13.4 million from warrant exercises, were finalized.

  • Significant Dilution

    The offering includes 8,571,429 ADSs (or pre-funded warrants) and two series of warrants (Series A-1 and A-2, each for 8,571,429 ADSs), priced at $0.70 per ADS and accompanying warrants, representing a notable discount to the current stock price of $0.84.

  • Critical Capital Infusion

    This financing is essential for the company, which recently received a Nasdaq delisting notice and issued a "going concern" warning, providing a lifeline for continued operations.

  • Placement Agent Fees

    H.C. Wainwright & Co. will receive a 7.5% cash fee and warrants to acquire 514,286 ADSs at an exercise price of $0.875.


Analysis · RDHL · Life Sciences

This 6-K filing details the definitive terms of a private placement, previously announced on June 18, 2026, which will raise $6 million upfront and potentially an additional $13.4 million from warrant exercises. For a company with a market capitalization of approximately $4.2 million that recently received a Nasdaq delisting notice and issued a "going concern" warning, this capital infusion is crucial for its continued operations. However, the offering is highly dilutive, with shares and warrants sold at a significant discount to the current market price, imposing a substantial cost on existing shareholders.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RDHL was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDHL - Latest Insights

RDHL
Oct 07, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4981
Real-time Price: $0.4252 info
Change: -$0.0729 (-15%) info
Market Cap: $3.751M info
RDHL
Sep 30, 2026, 4:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4797
Real-time Price: $0.4252 info
Change: -$0.0545 (-11%) info
Market Cap: $3.751M info
RDHL
Sep 01, 2026, 7:10 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.9195
Real-time Price: $0.4252 info
Change: -$0.4943 (-54%) info
Market Cap: $3.751M info
RDHL
Sep 01, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.9016
Real-time Price: $0.4252 info
Change: -$0.4764 (-53%) info
Market Cap: $3.751M info
RDHL
Aug 31, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.6303
Real-time Price: $0.4252 info
Change: -$0.2051 (-33%) info
Market Cap: $3.751M info